Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Current Deferred Revenue for 7 consecutive years, with $13.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue fell 53.29% year-over-year to $13.2 million; the trailing twelve-month figure through Jun 2026 stood at $13.2 million (down 53.29% YoY), and the FY2025 full-year result was $94.1 million, down 25.61% from the prior year.
• Current Deferred Revenue eased to $13.2 million in Q2 2026 per DNA's latest filing, from $14.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $222.6 million in Q4 2022 and bottomed at $13.2 million in Q2 2026.
• Historically, Current Deferred Revenue has averaged $88.6 million across 5 years, with a median of $68.4 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue surged 368.98% in 2022, then tumbled 80.56% in 2024.
• Over 5 years, Current Deferred Revenue stood at $222.6 million in 2022, then retreated by 9.03% to $202.5 million in 2023, then plunged by 37.53% to $126.5 million in 2024, then dropped by 25.61% to $94.1 million in 2025, then tumbled by 85.96% to $13.2 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $13.2 million, $14.9 million, and $94.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.